TG Therapeutics Inc (NASDAQ:TGTX) CFO Sean A. Power sold 32,006 shares of TG Therapeutics stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares of the company’s stock, valued at $4,398,444. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of TG Therapeutics Inc (NASDAQ:TGTX) opened at $9.10 on Friday. TG Therapeutics Inc has a 12-month low of $4.10 and a 12-month high of $15.35. The company has a market capitalization of $642.94, a PE ratio of -4.72 and a beta of 1.30.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.05). TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. equities analysts predict that TG Therapeutics Inc will post -1.87 EPS for the current year.

A number of institutional investors have recently modified their holdings of TGTX. State Street Corp increased its position in TG Therapeutics by 274.4% in the 2nd quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock valued at $26,515,000 after buying an additional 1,933,896 shares in the last quarter. Artal Group S.A. bought a new stake in TG Therapeutics in the 2nd quarter valued at about $5,025,000. Franklin Resources Inc. increased its position in TG Therapeutics by 20.6% in the 2nd quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock valued at $23,509,000 after buying an additional 398,916 shares in the last quarter. Kennedy Capital Management Inc. increased its position in TG Therapeutics by 151.6% in the 2nd quarter. Kennedy Capital Management Inc. now owns 565,178 shares of the biopharmaceutical company’s stock valued at $5,680,000 after buying an additional 340,545 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in TG Therapeutics by 14.3% in the 2nd quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock valued at $20,566,000 after buying an additional 255,844 shares in the last quarter. 50.41% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on TGTX shares. ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. HC Wainwright reissued a “buy” rating and issued a $33.00 price objective (up from $18.00) on shares of TG Therapeutics in a research report on Tuesday, November 14th. SunTrust Banks reissued a “buy” rating and issued a $28.00 price objective on shares of TG Therapeutics in a research report on Tuesday, October 3rd. B. Riley reissued a “buy” rating and issued a $21.50 price objective on shares of TG Therapeutics in a research report on Monday, December 11th. Finally, Raymond James Financial reissued a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $25.50.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/insider-selling-tg-therapeutics-inc-tgtx-cfo-sells-272051-00-in-stock/1797116.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.